Terra Biologics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Debt
  • Latest Deal Amount
  • $100K
Latest Deal Amount
  • Investors
  • 5

Terra Biologics General Information

Description

Producer of cyanobacteria-based agricultural technology intended to increase the production of rice and increase the fertility of the soil. The company's technology helps in an array of agricultural areas such as soil fertility, water retention and erosion reduction by using naturally occurring photosynthetic microorganisms that convert solar energy and nutrients to fix atmospheric nitrogen, enabling farmers to increase their harvest and earnings.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Agricultural Chemicals
Other Industries
Cultivation
Primary Office
  • 2120 South Warson Road
  • Saint Louis, MO 63124
  • United States
+1 (319) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Terra Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Debt - General 19-Jan-2015 $100K 00000 Completed Generating Revenue
1. Seed Round 07-Sep-2012 00000 00000 Completed Startup
To view Terra Biologics’s complete valuation and funding history, request access »

Terra Biologics Executive Team (2)

Name Title Board Seat Contact Info
Michael Ott Founder
You’re viewing 1 of 2 executive team members. Get the full list »

Terra Biologics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ag Ventures Alliance Venture Capital Minority 000 0000 000000 0
Linseed Capital Angel Group Minority 000 0000 000000 0
Missouri Technology Corporation Venture Capital Minority 000 0000 000000 0
Nebraska Angels Angel Group Minority 000 0000 000000 0
Nidus Partners Venture Capital Minority 000 0000 000000 0
To view Terra Biologics’s complete investors history, request access »